Jeff Arnold is chairman and CEO of Sharecare, a digital health company he founded with Dr. Mehmet Oz to help people access and manage all of their health resources in one place. Sharecare’s personalized and comprehensive platform connects consumers, employees and health plan members to the knowledge, evidence-based programs and health professionals they need by building each user a unique, dynamic health profile.
Under Jeff’s leadership, Sharecare has been recognized as best-in-industry by numerous organizations. For its innovations in digital health, Sharecare has received multiple Stevie® Awards – including a Silver Stevie for Company of the Year in the Health Products and Services and Pharmaceuticals category – as well as multiple honors from The Webby Awards, Appy Awards, Telly Awards and Digital Health Awards. Sharecare also has been named to Deloitte’s Technology Fast 500™, the Healthcare Informatics 100, the Association for Corporate Growth’s Fast 40, the Technology Association of Georgia’s Top 10 Innovative Technology Companies and “Emerging Company of the Year” by the Metro Atlanta Chamber.
Prior to Sharecare, Arnold was chairman and CEO of HowStuffWorks.com, an award-winning online resource used by millions of people each month which he sold to Discovery Communications, where he served as chief digital strategy officer, and chief architect of The Curiosity Project until December 2011.
In 1998, he founded and served as CEO of WebMD, the first healthcare company to harness the power of the Internet to create a destination for consumers, healthcare institutions and physicians to find trustworthy medical information. Before WebMD, Jeff founded Quality Diagnostic Services (QDS), a cardiac arrhythmia monitoring company which was one of the first companies to use the concept of telemedicine over 25 years ago.
Jeff has been widely recognized for his innovative contributions to media and healthcare during his career, both in his home state of Georgia as well as internationally. Recently, he was recognized by the Technology Association of Georgia as the state’s “preeminent technology visionary” when they presented him with the ‘Icons of the Industry’ Award. In 2013, Jeff was inducted into the Technology Hall of Fame of Georgia and also received the prestigious Phoenix Award, which recognizes companies and individuals who embody strength, tenacity and leadership in Georgia’s healthcare information technology industry. Bestowed with the Blumenthal Award by Johns Hopkins University in recognition of his exceptional ability to bridge business and technology, Jeff has received numerous other honors from organizations including the World Economic Forum; Ernst & Young, which named him Entrepreneur of the Year, Southeast; and The IndUS Entrepreneurs (TiE), who presented him with a Lifetime Achievement Award. Jeff also was inducted into the Honor Society of Nursing, Sigma Theta Tau International, as an Honorary Member for his superior achievements and contributions to the advancement of nursing and healthcare on both a national and global level.
Currently chairman of Forbes Travel Guide and co-chairman of Endeavor Atlanta, Jeff also has served on numerous boards for public, private and charitable organizations over the years.
BrightEdge is the American Cancer Society’s strategic venture philanthropy platform, targeting investments that advance the commercialization of advanced therapies to treat, detect, and prevent all types of cancer.
Prior to the BrightEdge Fund, Bob was a Sr. Partner at Harbert Growth Partners where he led the healthcare practice. His investments that have been realized where he served as a board member or board observer include Shipt – acquired by Target in 2017, Wellcentive – acquired by Royal Philips in 2016, nContact – acquired by Atricure in 2014 and Novamin – acquired by GSK in 2009.
He also serves on the boards of the Southeastern Medical Device Association, the Southern Capital Forum, the Innovation Depot, the Birmingham Venture Club, the Global Center for Medical Innovation and the True Vine Foundation.
Most recently, he was the Executive Director of Innovate Birmingham, an 18-month initiative in which he led a team to assess, evaluate and recommend to Birmingham’s economic development organizations strategies for accelerating the growth of that market’s technology-based economy. During this time, he also served as an Operating Advisor to Harbert Growth Partners, after stepping down as the Senior Partner and Healthcare Practice Leader in 2017. Prior to Harbert he was Vice President/General Manager of the Pharmacy Services Division at US Oncology, a privately held, vertically integrated cancer care provider network, that sold to McKesson in 2010. Prior to US Oncology, he was a Senior Executive at Cardinal Health where he served as Vice President/General Manager of New Ventures. Prior to Cardinal he was the founder and CEO of Surgical Innovations & Services, Inc. (SIS). Under his leadership, SIS became a leader in the emerging outsource management sector, with over 300 hospitals and surgery centers under contract.
Bob is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.
Shawn Hingtgen, Ph.D., is pioneering a new treatment for cancer using induced neural stem cells to deliver therapeutic agents at the UNC Eshelman School of Pharmacy. He is also the founder of Falcon Therapeutics, founded to advance the discoveries generated in the Hingtgen lab towards the clinic to redefine the care for patients with cancers that are currently incurable. The company’s initial successful research was also in glioblastoma, but they have developed their personalized tumor-homing cell therapy technology into a platform able to treat solid tumor cancers, childhood cancers and metastatic disease.
Hingtgen joined the School’s Division of Molecular Pharmaceutics and Pharmacoengineering as an assistant professor in 2012. He holds a joint appointment as an assistant professor in the Department of Neurosurgery at the UNC School of Medicine.
In 2014 he received the Young Investigator Award from the Society for Neuro-Oncology and was a finalist for the Damon Runyon-Rachleff Innovation Award from the Damon Runyon Cancer Research Foundation in 2013. He is the author of twenty-five refereed papers and articles with an h-index of 15 cited more than 700 times, as well as two book chapters.
Hingtgen completed his undergraduate work and earned his Ph.D. in anatomy and cell biology from the University of Iowa. He then completed postdoctoral fellowships with Ralph Weissleder, M.D., Ph.D., and Khalid Shah, Ph.D., at Harvard Medical School and Massachusetts General Hospital in Boston.
As Senior Director in External Science and Innovation at Pfizer, Linda Lohr leads external partnering efforts for Pfizer across the Southern and Central US. With over 20 years of experience in the pharmaceutical industry, Linda has worked in both small and large corporate environments from early through late stage drug development. She received her Ph.D. in chemistry from Yale, and did her post-doctoral work at Exxon-Mobil. Linda later joined Otsuka Pharmaceuticals, where she interfaced with scientists across academia, industry, and government and was subsequently recruited to join Pfizer where she’s held roles of increasing responsibility across R&D. In her current role, she established a new external partnering presence for Pfizer in Texas and across the Central and Southern US, and she launched Pfizer’s inaugural “ITEN” collaboration model — a novel, multi-year external partnership to identify new drug targets spanning multiple therapeutic areas. Linda continues to balance scientific strategy with business drivers to champion external collaborations across the Southern and Central US to support Pfizer’s R&D portfolio. Linda is the author of numerous external scientific publications and presentations and invited book chapters. She has won multiple awards for accelerating drug development and pioneering new technology approaches. In her free time, she is an artist and entrepreneur.
Pete joined ConMed Corporation in 2015 and is responsible for corporate strategy and M&A activities for the company. Prior to joining ConMed, Pete spent two years at Cardinal Health where he oversaw the strategic investment and M&A pipeline as well as new business formation efforts for the Medical Products Group within Cardinal Health’s Medical Segment. Prior to joining Cardinal Health, Pete spent fifteen years as a venture capitalist leading the healthcare and life sciences investment effort at Baird Venture Partners in Chicago for almost ten years, preceded by five years at Vector Fund Management, a life-sciences venture firm also based in Chicago. Prior to his career in venture capital, Pete spent over six years in corporate finance, mergers & acquisitions and merchant banking at JP Morgan & Co. and Banc One Capital Corporation.
Pete was the founding Chair of AdvaMed’s National Venture Capital Advisory Board and a founding Board member of the Mid-America Healthcare Investors Network (MHIN). Pete received his undergraduate degree in Business Administration and Finance from Miami University in Oxford, Ohio, and his MBA from the Amos Tuck School at Dartmouth.
Alan joined Vanderbilt in June of 2011, and is responsible for all aspects of the university’s technology protection and commercialization related to inventions made by all members of the Vanderbilt community. He is active in several licensing professional societies, and serves on a number of corporate and community boards. Alan has been a registered U.S. Patent Agent since 1999, and is a Certified Licensing Professional.
Prior to joining Vanderbilt, Alan served as the Director of Commercialization for Cleveland Clinic Innovations, the organization’s corporate venturing wing, where he was responsible for the organizations licensing operations. Alan came to the Cleveland Clinic from the University of Virginia, where he served as the Associate Director of the University of Virginia Patent Foundation.
Alan received his Masters Degree in nuclear physics from the University of Virginia, and graduated from Carnegie Mellon University in Pittsburgh, Pennsylvania with honors, receiving separate Bachelors Degrees in electrical engineering and physics.
Teo is the CEO of Boston Neurosciences, a Boston-based clinical stage venture-funded company developing non-invasive intracranial pressure monitoring technologies for neurological disease and glaucoma. He is also a managing partner in Salutramed, an Atlanta-based biomedical consulting firm, and Director of Life Sciences at Anglo-Scientific at the Royal Institution of Great Britain in London, an early stage VC. Prior to joining Boston Neurosciences, Teo served as a partner in two US venture capital funds, chaired the medical school at Queen’s University Belfast, and taught at the Program in Biomedical Entrepreneurship in the Harvard-MIT Program in Health Sciences and Technology. He trained in neurosurgery at the Massachusetts General Hospital, and is credited with the development of cortical stimulation systems for the treatment of epilepsy, intraventricular use of morphine for intractable pain, and other neurosurgical technologies.
Teo has served as a director of numerous public and private boards, and also of institutions such as the the Wharton School, the DuPree School of Management of the Georgia Institute of Technology and the Georgia Neurosurgical Society, which he also chaired. He is Director-elect of the American Association of Neurological Surgeons.
Teo holds an AB from Columbia, MD and MPH from Hopkins, MTS from Harvard, where he was the Joseph P Kennedy, Jr., Fellow, an MBA from Wharton, the DMedSc from Queen’s University Belfast and a DHC from the Technical University of Kaunas. He holds appointments at Queen’s and at Harvard Medical School and teaches at the National Venture Capital Institute. He is widely published, and is often invited to address innovation and safety in surgery. He is an editor of Neurosurgery.
Justin Klein joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of ChromaCode, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (NASDAQ: PHAS), Relievant MedSystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include Cartiva (acquired by Wright Medical), CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed’s Business Development Committee.
Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation’s first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.
Gladys Nunez joined Amgen in 1997 and currently leads diligence and completion of venture investments. Prior to Amgen Ventures in 2014, Gladys spent over 10 years in Amgen’s Technology licensing group prospecting, negotiating and establishing external alliances support for Amgen’s R&D organization. Prior to joining business development Gladys worked 7 years in R&D, concurrent between Amgen and AstraZeneca. Gladys holds an MS in Biochemical Pharmacology from the University of Southhampton in England.
Max Wallace has served as Chief Executive Officer of ABC2 since August, 2008. With his entrepreneurial biotechnology business background, Max is uniquely qualified to lead Accelerate Brain Cancer Cure and its venture philanthropy approach to finding a cure for brain cancer.
Prior to ABC2, Max served as Chief Executive Officer of TheraLogics, an anti-cancer biopharmaceutical company based on technology developed at the University of North Carolina at Chapel Hill. Prior to TheraLogics, he helped found and develop a number of other notable biotech companies, including Trimeris (NASDAQ TRMS), Sphinx Pharmaceuticals Corporation (now part of Eli Lilly & Company), SARCO (now part of PPD/Pharmaco), and Cogent Neuroscience.
Max also served as President of the Arbor Group, a consulting firm providing strategic advice to innovation-driven universities, companies and communities. In addition, Max was a member of the Board of Directors of the Emerging Companies Section of the Biotechnology Industry Association (BIO), helped found and served as Chairman of the North Carolina Innovation Foundation and served as a Senior Fellow in Leadership and Innovation at the Institute for Emerging Issues at North Carolina State University, working on issues of public policy related to the development and commercialization of innovative technologies. He was a founding director of Duke University’s investment management company and was legal counsel for the Duke Medical Center.
Max earned a B.A. from Duke and a J.D. from the University of Florida.
Jed Cohen joined LEERINK Partners as a Managing Director in 2009 to cover the medical technology sector. Jed has over 24 years of Healthcare Investment Banking experience, including 12 years at
Citigroup and three years at UBS prior to joining LEERINK. Jed’s transaction experience includes advisory work and financing assignments with clients across the healthcare industry, with an exclusive focus on “middle market” / emerging growth segments of the medical technology industry since 2000. Jed’s passion is aligning with breakthrough medical technology companies that are looking to create new markets or disrupt existing markets. He received a Bachelor of Science in Economics from the University of Pennsylvania’s Wharton School.
Doug currently serves as a Business Advisor and Technical Specialist with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia. In this role, Doug participates in strategy development, U.S. and international patent prosecution, licensing, patentability and freedom to operate analysis and transactional due diligence. Doug’s areas of expertise include molecular biology, drug discovery, pre-clinical drug development, licensing, biotechnology, and early-stage venture capital investing. Doug’s experience as a life sciences investor and entrepreneur provides him with unique insight when assisting clients.
Prior to joining the firm, Doug served as President and CEO of Altiris Therapeutics. Altiris is an early-stage biopharmaceutical company focused on the development of novel small molecule drugs that inhibit the chemokine receptor CXCR4 for use in stem cell mobilization and other indications. Doug accepted the role with Altiris as board member and investor in a predecessor company, Metastatix, Inc., and was responsible for recapitalizing and repositioning the company with support of several of the original investors.
Prior to Altiris, Doug was the co- founder and CEO of Regado Biosciences, which went public, merged with Tobira Therapeutics and was ultimately purchased by Allergan. Under his leadership, the company raised $50M across three venture capital financings and advanced its lead program through three Phase I studies and a Phase 2a study. Doug led the initial investment and company formation activities for Regado while a Principal at the Aurora Funds, an early-stage life sciences venture capital fund. While at Aurora, Doug served on the Board of Directors and led investments in Regado (founding investor), Metabolon (founding investor), Cropsolution, Metastatix, and Tissue Informatics (acquired by Paradigm Genetics).
Prior to joining Aurora, Doug was a Director of Business Development at Paradigm Genetics (acquired by Clinical Data). Doug also spent four years at Incyte Pharmaceuticals (INCY), where he was the manager of the cDNA Library Construction Group. In addition, Doug worked as a Research Associate at Stratagene Cloning Systems in La Jolla, California.
Doug is actively involved in the life sciences community in the Southeast region, including leadership roles with the BioMed Investors Network and Southeast BIO (SEBIO). In connection with both, he is involved in identifying and screening promising life sciences companies seeking angel and venture investment.
Doug received a Bachelor of Arts in Biology, with a minor in Chemistry, from the University of San Diego and a MBA from the Kenan-Flagler Business School at the University of North Carolina in Chapel Hill, NC.
Chuck has over twenty five years of experience in biopharmaceutical R&D, business development and corporate venture capital investing. Since 2013, Chuck has been a member of AbbVie’s corporate Venture Investment team in Cambridge, MA focusing on early-stage investments in life sciences. Prior to joining the Ventures team, he served as a Director in Abbott’s Global External Research organization where he was responsible for the identification, assessment, and development of early-stage partnerships across Abbott’s therapeutic areas. Chuck served as Vice President of Discovery at AtheroGenics, Inc leading teams to advance several programs into the clinic and started his career at Human Genome Sciences. Dr. Kunsch obtained his Ph.D. from Penn State’s College of Medicine, is an inventor on more than 30 patents and has authored more than 45 peer-reviewed manuscripts, reviews and book chapters.
Tim Patrick is the President, Chief Executive Officer and co-founder of Cartiva. Tim has over 30 years of successful leadership experience in general management and product commercialization in the medical device industry. Prior to founding Cartiva, Tim was President and CEO of Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.
Prior to co-founding Proxima Therapeutics in 1996, Tim was President of Gesco International, the leading manufacturer of peripherally inserted central venous catheters, acquired by C.R. Bard. Before serving as President of Gesco International, he ran two high growth divisions for McGaw Inc., an infusion equipment and drug delivery company which was acquired by B. Braun. He also held a number of sales and sales management positions at American Hospital Supply Corporation.
Tim has served on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the Board of the Georgia Tech Coulter Grant Committee and on the Board of Georgia Bio. Tim is an inventor on a number of medical device patents. He earned his BA in Zoology from Miami University in Ohio.
Broad transaction experience and a wide network enable Scott to provide assistance to companies when raising capital, forming strategic partnerships and analyzing exit options.
Prior to joining Pappas Capital in 2006, Scott was an investment manager and research analyst for Silverback Asset Management’s life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focused on healthcare venture investments, and prior to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New York, London and Hong Kong.
Scott currently serves as a director for Reneo Pharmaceuticals, and as an observer for 4D Molecular Therapeutics, Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies, Milestone Pharmaceuticals, Thrasos Therapeutics and VelosBio. He previously served as a director for Rotation Medical (acquired by Smith & Nephew), and as an observer for LipoScience (NASDAQ: LPDX) (acquired by LabCorp) and TESARO (NASDAQ: TSRO). Scott is also a board member for the Council for Entrepreneurial Development (CED) and a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research.
Bob Creeden, Managing Director of the UVA LVG Seed Fund & New Ventures at the UVA Licensing & Ventures Group (LVG) supports the creation of high-quality ventures based on University technologies and leads the day-to-day operations of the $10 million investment fund.
Since joining LVG in September 2016, Creeden has facilitated four strategic investments in companies emerging from the University portfolio, oversaw the Fund’s first exit from TypeZero Technologies, and launched a curriculum course at the Darden School of Business titled ‘Due Diligence in Seed Funds,’ which is now in its third year.
In addition to more than 30 years of experience in commercializing new technologies, both as an entrepreneur and investor, Creeden has more than 20 years of experience as an early stage venture capitalist in the Boston area. He served as Vice President of the Massachusetts Technology Development Corporation, an early stage venture firm that funds technology-based companies in Massachusetts, General Partner at Egan-Managed Capital, a $150 million dollar Boston-based venture fund, and in 2005 he established and implemented the Partners Innovation Fund, ($35M) at Partners HealthCare.
Bob holds a BA in Economics from Holy Cross College and an MBA from Suffolk University, and for six years was a faculty member in the Entrepreneurial Leadership Program of the Gordon Institute at Tufts University.
Steve brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts and was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM. Steve started his career as a medicinal chemist with the Squibb Institute for Medical Research and held positions of increasing responsibility for multiple projects in cardiovascular disease.
Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.
Steve is a General Partner with Lilly Ventures and currently sits on the boards of Cavion, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Nimbus, and Lysosomal Therapeutics. Steve also serves as the CEO for Esanex.
Dennis Liotta, PhD, serves as Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor in the Department of Chemistry at Emory University. Dr. Liotta is recognized as one of the premier discoverers of novel therapeutics in the United States, having been the inventor of record for several clinically important antivirals and associated with the invention of ten FDA approved therapeutics.
Dr. Liotta joined Emory in 1976. Since that time, he has authored over 230 research publications and more than 70 issued US patents. Dr. Liotta has also supervised numerous postdoctoral and graduate students and has received several teaching awards, including Emory University’s Thomas Jefferson Award, the highest faculty honor given at Emory. He is a Fellow of both the American Association for the Advancement of Science and the American Chemical Society. Dr. Liotta was elected to the National Academy of Inventors in 2014 and the Medicinal Chemistry Hall of Fame in 2010. Dr. Liotta also is the co-director of the Republic of South Africa Drug Discovery Training Program and a member of the Discovery and Developmental Therapeutics Research Program at Winship.
Dr. Liotta earned his PhD in Organic Chemistry from the City University of New York in 1974. Following this, he completed his postdoctoral fellowship at Ohio State University.
Owen B. Samuels MD received his M.D. degree from the State University of New York Health Science Center at Brooklyn and completed his internship and residency training at the University of Rochester Medical Center. He completed a Cerebrovascular Disease Fellowship at Emory University and a second fellowship in Neurologic and Neurosurgical Neurointensive Care Medicine at the University of Pennsylvania.
Dr. Samuels was instrumental in the redevelopment of Emory University Hospital’s Neurointensive Care Unit. In 2007, Emory opened its 20-bed, neurosciences ICU that allows for centralization of the most critical medical services for patients suffering from severe neurologic and neurosurgical brain injury. Emory’s new unit is one of the largest and busiest in the country, and one of only a few of this type of unit in the Southeast. It provides an unparalleled level of comfort and convenience, and most importantly, the integration of family members who wish to remain near their loved ones. The Neurosciences Critical Care Unit at Emory University Hospital was selected as the recipient of the 2008 ICU Design Citation Award.